

## CLAIMS

1. An oily pharmaceutical composition based on peroxidised lipids and on silica, characterised in that it contains, as essential constituents, peroxidised lipids which have a degree of peroxidation of between 5 and 600 milli-equivalents per kilogram, and silica which is dispersed within said peroxidised lipids at a concentration by weight of greater than or equal to 0.5% and less than 4%.
2. The pharmaceutical composition according to claim 1, characterised in that it contains 0.5 to 3.5% by weight of silica.
3. The pharmaceutical composition according to claim 1 or 2, characterised in that it contains 0.5 to 2% by weight of silica.
4. The pharmaceutical composition according to claim 1 to 3, characterised in that it is in a form which is compatible with a use as a spray.
5. The pharmaceutical composition according to one of claims 1 to 4, characterised in that the silica is in a form of colloidal silica.
6. The pharmaceutical composition according to one of claims 1 to 5, characterised in that its cinematic viscosity upon preparing said composition, measured at 20°C by means of a capillary viscometer, is between 26.6 and 44.4 mm<sup>2</sup>/s.
7. The composition according to one of claims 1 to 6, characterised in that its density is  $0.95 \pm 10\%$ .
8. The composition according to one of claims 1 to 7, characterised in that said peroxidised lipids have a degree of peroxidation of between 5 and 600, preferably between 30 and 500, more preferably between 50 and 300, more preferably between 50 and 150 milli-equivalents per kilogram.

9. Use according to one of claims 1 to 8, characterised in that said peroxidised lipids comprise, as main constituents, partially oxidised triglycerides of general formula :



in which the radicals R are partially peroxidised C18 unsaturated acids.

10. A pharmaceutical composition according to one of claims 1 to 9, characterised in that said peroxidised lipids are obtained by peroxidation of lipids or of fats of natural origin, preferably of lipids originating from a natural plant oil.

11. The pharmaceutical composition according to claim 10, characterised in that the natural oil is selected from the group consisting of sweet almond oil, hazelnut oil, groundnut oil, maize oil, grapeseed oil, sesame oil, and safflower oil, and their mixtures.

12. Use of peroxidised lipids as defined in one of claims 1 or 8 to 11 for the preparation of a pharmaceutical composition intended for the treatment of xerostomia.

13. Use according to claim 12, characterised in that said composition contains at least 0.5% by weight and less than 4% by weight of colloidal silica, preferably between 0.5 and 3.5% by weight, more preferably between 0.5 and 2% by weight.